8-K: BioAtla Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Clinical Program Updates

BioAtla reports financial results for Q4 and full year 2024, highlights clinical progress, and announces cost-reduction measures including a workforce reduction.

Summary

• BioAtla announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company is focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors.
• A Phase 1 dose-escalation study for CAB-EpCAM x CAB-CD3 (BA3182) is ongoing, with a data readout expected in mid-2025 and dose expansion data anticipated in the first half of 2026.
• Mecbotamab vedotin (CAB-AXL-ADC) showed exceptional overall survival in mKRAS NSCLC patients, with 66% alive at one year and 58% at two years.
• Ozuriftamab vedotin (CAB-ROR2-ADC) demonstrated anti-tumor activity in treatment-refractory, metastatic HPV-positive squamous cell carcinoma of the head and neck (SCCHN).
• The company's cash balance was $49 million at year-end 2024.
• Cost-reduction measures are expected to extend the company's financial runway beyond key clinical readouts in the first half of 2026.
• A workforce reduction of approximately 30% was announced to streamline operating costs.
• The company estimates one-time cash payments of approximately $0.6 million related to the workforce reduction, primarily in the second quarter of 2025.
• Research and development (R&D) expenses were $11.6 million for the quarter ended December 31, 2024, compared to $22.7 million for the same quarter in 2023.
• General and administrative (G&A) expenses were $4.6 million for the quarter ended December 31, 2024, compared to $5.9 million for the same quarter in 2023.
• Net loss for the quarter ended December 31, 2024, was $14.9 million, compared to a net loss of $26.9 million for the same quarter in 2023.
• Net cash used in operating activities for the full year ended December 31, 2024, was $72.0 million, compared to $104.0 million for the same period in 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company is reducing its workforce to extend its cash runway, clinical data for key programs is encouraging, and management expresses confidence in future progress.

Positives

• Mecbotamab vedotin shows promising overall survival rates in mKRAS NSCLC patients.
• Ozuriftamab vedotin demonstrates anti-tumor activity in a difficult-to-treat SCCHN population.
• The company is taking steps to extend its cash runway through cost reductions.
• Phase 1 dose escalation for BA3182 is ongoing and on track with data readout mid-2025.
• Observed multiple patients with tumor reduction, including a colorectal cancer patient with stable disease for greater than one year in the BA3182 trial.
• Evalstotug is well-tolerated with 25% grade 3 (no grade 4) imAEs in patients with exposures up to 18 weeks.

Negatives

• The company is implementing a workforce reduction of approximately 30%.
• The company's cash balance decreased from $111.5 million at the end of 2023 to $49.0 million at the end of 2024.
• R&D expenses decreased due to lower overall enrollment across clinical trials due to program prioritization in 2023.

Risks

• The company's ability to achieve the expected benefits of the workforce reduction is uncertain.
• The company may need additional funding to continue development of its CAB technology platform and product candidates.
• Potential delays in clinical and preclinical trials could impact timelines.
• Unfavorable new clinical data or further analyses of existing data could negatively affect the company's prospects.
• The company's dependence on the success of its CAB technology platform poses a risk.
• The company's ability to form collaborations and partnerships with third parties is not guaranteed.
• The company relies on third parties for manufacturing, supply, and clinical trial conduct, which introduces potential risks.
• Geopolitical or macroeconomic events outside of the company's control could have adverse impacts.

Future Outlook

BioAtla expects cost reductions from the realignment of resources and focus on prioritized programs to provide sufficient runway to fund operations and achieve key clinical readouts in the first half of 2026.

Management Comments

• We are encouraged by the differentiated clinical outcomes observed in our evolving CAB platform program datasets, said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc.
• We continue to observe encouraging results, with multiple patients achieving tumor reduction and tolerating the therapy over many months without progression.
• We are also observing meaningful improvement in our clinical datasets across our CAB platform programs in terms of tumor reduction and overall survival in key unmet need patient populations.
• Finally, we restructured the organization to further reduce costs, extend runway and prioritize new patient recruitment to programs that we believe can provide transformative results for our patients and shareholders alike.

Industry Context

BioAtla is operating in the competitive biotechnology industry, focusing on novel antibody therapeutics for solid tumors. The company's CAB platform aims to offer more selective targeting and greater efficacy with lower toxicity compared to traditional antibodies. The clinical data presented for Mecbotamab vedotin and Ozuriftamab vedotin suggests potential differentiation in specific cancer subtypes.

Comparison to Industry Standards

• The reported overall survival rates for Mecbotamab vedotin in mKRAS NSCLC patients (66% at one year, 58% at two years) exceed the reported standard of care, suggesting a potential improvement over existing treatments.
• The 45% ORR observed with Ozuriftamab vedotin in treatment-refractory SCCHN patients is compelling, especially considering the limited treatment options available for this population.
• Companies like Seagen (now part of Pfizer) and ImmunoGen are key players in the ADC space, and BioAtla's CAB-ADC programs are competing in this field.
• The development of bispecific T-cell engagers like BA3182 puts BioAtla in competition with companies like Amgen and Roche, who have approved or investigational T-cell engagers.

Stakeholder Impact

• Shareholders may be impacted by the workforce reduction and restructuring, but potentially benefit from the extended cash runway and promising clinical data.
• Employees are affected by the workforce reduction of approximately 30%.
• Patients with solid tumors may benefit from the development of novel CAB antibody therapeutics.
• Potential collaborators and partners may be interested in the Phase 2 assets being advanced through corporate partnerships.

Next Steps

• Continue Phase 1 dose escalation for BA3182 with data readout expected mid-2025 and dose expansion data anticipated 1H 2026.
• Position Mecbotamab vedotin for a future pivotal trial with Phase 2 clinical data readout in 1H26.
• Advance Phase 2 programs for ozuriftamab vedotin and evalstotug through corporate partnerships.
• Continue patient recruitment to prioritized programs.

Key Dates

Keywords

BioAtla, CAB technology, clinical trials, financial results, oncology, antibody therapeutics, workforce reduction, Mecbotamab vedotin, Ozuriftamab vedotin, BA3182